Bonus Biogroup Ltd.
18.00
ILA
+0.10
(+0.56%)
ISIN
IL0004850116
Return %
Stock
S&P 500
1Y
-18.18
14.20
3Y
24.14
81.12
5Y
-86.00
68.34
Capital Structure
ILS
•
in mil. unless spec.Working Capital
ILS
•
in mil. unless spec.Growth Rates
ILS
•
in mil. unless spec.Semi-annual Revenue
ILS
•
in mil. unless spec.Semi-annual Earnings Per Share
ILS
•
in mil. unless spec.Semi-annual Dividends Per Share
ILS
•
in mil. unless spec.Company Description
- CEO
- Shai Meretzki
- Full Time Employees
- 42
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- Matam Advanced Technology Park Haifa HA Israel 3190501
- IPO Date
- Aug 20, 1993
- Website
- bonusbiogroup.com
- Similar Companies
- Business
- Bonus BioGroup Ltd. (TASE: BONS) develops tissue engineering and cell therapy products addressing unmet needs in bone regeneration, inflammation, and tissue repair. The company offers investigational therapies including BonoFill, a personalized autologous viable bone graft utilizing patient-derived mesenchymal cells combined with a three-dimensional biocompatible mineral scaffold for maxillofacial, dental, and orthopedic bone defect reconstruction; and MesenCure, an enhanced allogeneic mesenchymal cell therapy designed to modulate inflammation, promote tissue repair, and treat respiratory distress in conditions such as COVID-19 pneumonia and acute respiratory distress syndrome (ARDS). These products target severe conditions with limited treatment options, leveraging proprietary platforms for clinical-stage development in regenerative medicine. Bonus BioGroup Ltd., founded in 2008 and headquartered at Matam Advanced Technology Park in Haifa, Israel, operates primarily from GMP-compliant facilities established in 2013 and expanded in 2022 to support research, development, and clinical manufacturing. The company conducts operations in Israel with clinical trials extending to international sites, including collaborations with the Israel Institute for Biological Research, The Jackson Laboratory in the USA, and St. Catherine's Hospital in Croatia. It serves patient populations in orthopedics, maxillofacial surgery, and critical care, focusing on multi-billion-dollar markets underserved by current therapies. Recent developments include completion of a Phase II trial for BonoFill in maxillofacial bone defects in 2024, achieving the primary efficacy endpoint of sufficient bone height for dental implants in 90% of cases with no treatment-related severe adverse events; ongoing Phase II evaluation for limb bone defects; and FDA clearance in February 2025 for a MesenCure Phase III trial in COVID-19 respiratory distress, with plans to amend the protocol for broader ARDS indications pending approval. In 2024, the Israeli Ministry of Health certified BonoFill and MesenCure production under cGMP standards for Phase III trials, aligning with WHO guidelines. A Phase III study for BonoFill in jaw bone defects is planned for 2026 in the United States, subject to regulatory approval.